HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: hrt.2007.117390v1 94/5/585    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Parissis, J T Articles by Kremastinos, D T PubMed PubMed Citation Articles by Parissis, J T Articles by Kremastinos, D T Topic Collections Related Article

Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure

Heart Failure Clinic, Second Department of Cardiology, Attikon University Hospital, Athens, Greece

Correspondence to:
John T Parissis, MD, FESC, Aftokratoros Irakliou 17, 15122 Maroussi, Athens, Greece; jparissis{at}yahoo.com

ABSTRACT
Background: Depression is common among patients with chronic heart failure (CHF) and has been independently associated with a poorer prognosis.

Purpose: This study evaluated the clinical and prognostic value of depression scales (Beck Depression Inventory (BDI), Zung Self-rating Depression Scale (Zung SDS)) along with plasma B-type natriuretic peptide (BNP) in CHF.

Methods: 155 hospitalised CHF patients (ejection fraction 26.9% (SD 6.4%)) were studied by depression (BDI, Zung SDS) and functional questionnaires (Kansas City Cardiomyopathy Questionnaire (KCCQ), Duke Activity Status Index (DASI)), BNP and 6-minute walk test (6MWT). Patients were followed for 6 months for cardiovascular events, including death from any cause or rehospitalisation for CHF decompensation.

Results: Seventy-six (49%) patients with depressive symptoms, as estimated by both scales, had significantly lower DASI and KCCQ scores (13.2 (SD 9.9) vs 23.6 (SD 13.0) and 26.6 (SD 15.0) vs 45.0 (SD 17.0), respectively; p<0.001), higher BNP (921 (SD 889) vs 439 (SD 267) pg/ml, p = 0.001) and reduced 6MWT (270 (SD 130) vs 337 (SD 133); p<0.001). According to logistic regression analysis, Zung SDS and BNP were independently associated with adverse clinical outcomes; values of Zung SDS 40 and of BNP 290 pg/ml predicted future events with a sensitivity of 82% and 94% and a specificity of 45% and 46%, respectively. The combination of Zung SDS plus BNP had an additive prognostic value, predicting events with a sensitivity of 77% and a specificity of 70% (event-free survival: Zung <40 and BNP <290 pg/ml; 170 (SD 9) days; Zung 40 and BNP <290 pg/ml, 159 (SD 14) days; Zung <40 and BNP 290 pg/ml, 118 (SD 15) days; Zung 40 and BNP 290 pg/ml, 73 (SD 8) days, p<0.001).

Conclusions: CHF patients with depressive symptoms have impaired physical activity, associated with excessive neurohormonal activation. Among the studied scales, Zung SDS seemed to independently predict clinical outcome, especially in patients with increased plasma BNP concentration. Hence, the combination of those two modalities provides a practical means for risk stratification in CHF.

This article has been cited by other articles:

				C. Herrmann-Lingen and B. Pieske Natriuretic peptides or psychometric tests? Prognostic markers in congestive heart failure Heart, May 1, 2008; 94(5): 545 - 546. [Full Text] [PDF]